News | Artificial Intelligence | January 06, 2021

FDA Clears Ultromics Echocardiography AI for Automated Identification of Coronary Artery Disease

First-of-kind artificial intelligence solution in cardiac ultrasound will help clinicians diagnose disease

Ultromics will offer EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.


January 6, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Ultromics' EchoGo Pro, an artificial intelligence (AI) powered, outcomes-driven, decision support tool to automatically identify coronary artery disease (CAD) in echocardiograms

CAD indications can be subtle. Misdiagnosis happens with one in five patients potentially resulting in poor treatment and outcomes, which is compounded by the subjectivity of interpretation between clinicians. With the use of EchoGo Pro, clinicians have additional insights, derived from AI models trained on large datasets in Oxford, U.K. The technology improves disease prediction and supports more accurate diagnosis. This should lead to earlier suitable interventions, reducing cardiac events and improving patient care. 

"Coronary artery disease is a huge global burden, affecting tens of millions of peoples' lives worldwide," said Ross Upton, Ph.D., founder and CEO of Ultromics. "Heart disease is the biggest killer globally and this number is increasing daily. Our goal is to help doctors detect CAD more accurately, improving patient outcomes and saving lives."

Ultromics will offer EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. By automating echocardiogram analysis as part of a cloud service, Ultromics hopes to save clinicians even more time when compared to traditional on-site solutions.

"COVID-19 has placed an even greater pressure on cardiac care and looks likely to have lasting implications in terms of its impact on the heart" explained Upton. "The healthcare industry needs to quickly pivot towards AI powered automation to reduce the time to diagnosis and improve patient care. To help support this shift and save countless lives we are making the EchoGo suite as complete and automated as possible to help clinicians rapidly assess disease and provide early, appropriate intervention. FDA approval for EchoGo Pro is the next step on our innovation journey to transform echocardiography and impact patients' lives"

EchoGo Pro is now clinically available in the European Union and U.S., and is being rolled out in the U.K. National health Service (NHS) as part of the prestigious NHSx award and assessed at Mayo Clinic. 

Ultromics is a global health technology firm which provides autonomous echocardiography analysis through innovative AI solutions. The company developed the first fully automated solution for echocardiography and strain analysis. The platform, EchoGo, is a cloud-based AI service which delivers analysis to any vendor within minutes and with zero variability through its zero-click, full automation workflow. The technology was developed at the University of Oxford and built-in partnership with the NHS and has since raised over £20 million to help bring diagnostic quality to hospitals, improve patient care, and help make valuable resource and cost savings. 

For more information: www.ultromics.com

 

Related AI Content:

How Will Artificial Intelligence Impact Healthcare?

FDA Clears AI-powered Cardiac Echo Analysis and Quantification by Ultromics

Mayo Clinic Uses Artificial Intelligence to Help Assess Cardiac Danger From COVID-19

Ultromics Earns Frost & Sullivan Innovation Award for Pioneering AI-based Cardiac Echo Software


Related Content

News | Artificial Intelligence

September 22, 2022 — Medical imaging specialist Avicenna.AI announced a groundbreaking partnership with the MedTech ...

Home September 22, 2022
Home
News | Artificial Intelligence

September 2, 2022 — In patients undergoing echocardiographic evaluation of cardiac function, preliminary assessment by ...

Home September 02, 2022
Home
News | Artificial Intelligence

August 29, 2022 — In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and ...

Home August 29, 2022
Home
News | Artificial Intelligence

August 18, 2022 — Six digital healthcare start-ups from five countries have officially become the first cohort of the ...

Home August 18, 2022
Home
News | Artificial Intelligence

August 16, 2022 — Dyad Medical, Inc., the developer of the cloud-based AI technology for cardiac image analysis ...

Home August 16, 2022
Home
News | Artificial Intelligence

August 11, 2022 — The recent deals and collaborations in the medical device space indicate a growing interest in ...

Home August 11, 2022
Home
News | Artificial Intelligence

July 25, 2022 — Blackford, the platform for medical imaging applications and AI, and Us2.ai today announced their ...

Home July 25, 2022
Home
News | Artificial Intelligence

July 19, 2022 — Employing artificial intelligence to help improve outcomes for people with cardiovascular disease is the ...

Home July 19, 2022
Home
News | Artificial Intelligence

July 14, 2022 — Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a ...

Home July 14, 2022
Home
News | Artificial Intelligence

July 7, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American ...

Home July 07, 2022
Home
Subscribe Now